A Short Intro for Hillstream BioPharma Investors

By Blake Campbell • Tuesday, January 31 12:00 • Permanent Link

A strong performer from today's morning trading session is Hillstream BioPharma, whose shares rose 105.5% to $1.38 per share. For those of you thinking about investing in the stock, here is a brief value analysis of the stock using the company's basic fundamental ratios.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) ratio of 4.07. In contrast, Hillstream BioPharma has a trailing 12 month P/E ratio of -3.5 and a P/B ratio of 2.2.

Hillstream BioPharma has moved -83.0% over the last year compared to -11.6% for the S&P 500 — a difference of -71.4%. Hillstream BioPharma has a 52 week high of $4.24 and a 52 week low of $0.3.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.